Cofilin Drives Cell Invasive and Metastatic Responses to TGF-β in Prostate Cancer

1Joanne Collazo, 2Beibei Zhu, 2Spencer Larkin, 3Sarah K. Martin, 2Hong Pu, 4Craig Horbinski, 5Shahriar Koochekpour and 1, 2, 3, 4Natasha Kyprianou

1Departments of Toxicology, 2Urology, 3Molecular and Cellular Biochemistry and 4Pathology, University of Kentucky College of Medicine, Lexington, Kentucky, USA.

5 Departments of Cancer Genetics and Urology, Roswell Park Cancer Institute, Buffalo, New York, USA

Address correspondence to:
Dr. Natasha Kyprianou
Combs Research Building, Rm 306
University of Kentucky Medical Center
Lexington, KY 40536

E-mail: nkypr2@uky.edu
Tel; 1859-323-9812

Running title: TGF-β Functional Switch by Cofilin in Prostate Cancer

Abbreviations: CFL, cofilin, TGF-β, Transforming Growth Factor Beta, EMT, Epithelial to Mesenchimal Transition, ECM, Extracellular Matrix, GFP, Green Fluorescent Protein, MTT, (3-(4,4,5-Dimethylthiazol-2-yl)-2,5-diphenytertazolium bromide, PCR, polymerase chain reaction; PMSF, phenylmethanesulfonylfluoride, PBS, Phosphate Buffered Saline, SDS – PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis, LIMK, Lim domain kinase; ROCK1, Rho-associated, coiled-coil containing protein kinase 1; TRAMP, transgenic adenocarcinoma of the mouse prostate, DAB, diaminobenzidine, CAFS, cancer associated fibroblasts.

Disclosure of Conflicts of Interest. The authors disclose no potential conflicts of interest.
Abstract

Cofilin (CFL) is an F-actin severing protein required for the cytoskeleton reorganization and filopodia formation, which drives cell migration. CFL binding and severing of F-actin is controlled by Ser3 phosphorylation, but the contributions of this step to cell migration during invasion and metastasis of cancer cells are unclear. In this study we addressed the question in prostate cancer cells, including the response to TGF-β, a critical regulator of migration. In cells expressing wild-type CFL, TGF-β treatment increased LIMK-2 activity and cofilin phosphorylation, decreasing filopodia formation. Conversely, constitutively active CFL (SerAla) promoted filipodia formation and cell migration mediated by TGF-β. Notably in co-cultures of prostate cancer epithelial cells and cancer associated fibroblasts, active CFL promoted invasive migration in response to TGF-β in the microenvironment. Further, constitutively active CFL elevated the metastatic ability of prostate cancer cells in vivo. We found that levels of active CFL correlated with metastasis in a mouse model of prostate tumor and in human prostate cancer, CFL expression was increased significantly in metastatic tumors. Our findings show that the actin severing protein CFL coordinates responses to TGF-β that are needed for invasive cancer migration and metastasis.
Introduction

One out of six men will be diagnosed with prostate cancer during their lifetime. One out of thirty-six patients will not survive the disease. Death from prostate cancer results when cancer cells become metastatic after invading lymph nodes and blood vessels and migrate to the bone (1). The mainstay of treatment for metastatic prostate cancer has been androgen ablation conferring improved survival to patients with advanced disease (2). The apoptotic response to androgen ablation is the underlying mechanism driving tumor regression and therapeutic benefit in prostate cancer patients (3). The majority of prostate tumors recur however emerging as castration-resistant causing mortality, due to distinct molecular and genetic changes reactivating the androgen receptor (AR) signaling and conferring resistance to androgen-deprivation induced apoptosis (4,5). Dynamic interactions between cancer cells, and the tumor microenvironment consisting of the reactive stroma (6, 7), inflammatory cells, angiogenic vessels, fibroblasts and components of the ECM, dictate tumor invasion (8-10) and confer androgen-insensitivity in metastatic prostate cancer (11).

Cancer metastasis is regulated by signaling contributions from the microenvironment promoting cell detachment from the primary tumor and extracellular matrix (ECM) (12,13), acquisition of epithelial-mesenchymal transition (EMT) phenotype and invasion into the surrounding tissue (14), resistance to anoikis (15, 16), and migration via a chemoattractive path to a metastatic site (17-18). A distinct molecular program regulates the adhesion, EMT, migratory and invasive properties of disseminating tumor cells, all processes impacted by the dynamics of the cytoskeleton (16, 19). The cellular cytoskeleton consists of a dynamic net of actin filaments rapid polymerization and depolymerization of which, allows the cell to move toward extracellular stimuli (20-22). The ADF/cofilin protein is a small (19 kDa) actin
binding protein and the major regulator of the actin dynamics via the binding and severing of the filamentous actin form (23, 24). CFL binding causes a reduction in actin filament rotation allowing a free barbed end for the addition of new actin monomers (25, 26). CFL phosphorylation on Ser3 by LIMK-2 inhibits its binding to G actin (monomeric actin) and F-actin (filamentous actin) and severing of the actin filament in mammalian cells (19, 27). The Rho-associated, coiled-coil containing protein kinase 1 (ROCK1), is responsible for LIMK-2 phosphorylation and activation (28, 29). Actin polymerization regulated by CFL dephosphorylation/activation is a convergence point in the intracellular network through which extracellular stimuli impact actin cytoskeleton, invasion and apoptosis (21, 25, 30).

Transforming growth factor-β (TGF-β) functionally contributes to tumor progression to metastasis via its critical control of apoptosis and proliferation in the early stages of tumorigenesis, and its ability to promote angiogenesis, migration, invasion and immunity in late stages of metastatic spread (31-33). TGF-β signaling is propagated via (serine threonine kinases) transmembrane receptors (TβRI and TβRII), activation of which leads to downstream regulation of SMADs intracellular effectors in target cells, including prostate cancer (34-36). The mechanism via which TGF-β is functionally converted from a suppressor of pre-malignant cells to a tumor progression supporter of metastasis is unknown (37). Elucidating the contribution of the actin cytoskeleton to this critical phenomenon in prostate tumorigenesis will enable a novel platform for defining predictive markers of metastasis, as well as potential therapeutic targets. CFL was previously identified in this laboratory as a Smad-independent intracellular effector of TGF-β signaling in prostate cancer cells (38). This study investigated the role of active CFL in directing TGF-β to elicit metastatic responses in prostate cancer. We generated a series of cofilin phosphorylated/dephosphorylation mutants
determining the actin severing activity and their impact on prostate tumor aggressive behavior was characterized in the context of the microenvironment in vitro and in vivo. Our findings support a functional contribution of active (dephosphorylated) coflin to prostate cancer invasive and metastatic properties via switching TGF-β attributes.
Materials and Methods

Cell Culture and Transfections

The human prostate cancer cell lines PC-3 and LNCaP, was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). Cell lines were obtained every year between 2009-2013 and have been authenticated and tested for mycoplasma in August 2009, October 2010, May 2011, November 2012 and June 2013 by STR (method of Masters et al 2012 (Authentication of Human Cell Lines: Standardization of STR Profiling [DDC Medical]). The LNCaP TβRII cells are stable transfectants established in our laboratory with restored sensitivity to TGF-β by overexpressing the human TβRII receptor (34). Primary cultures of human prostate cancer associated fibroblasts (CAF s) were established from radical prostatectomy specimens (from prostate cancer patients) by Dr. S. Koochekpour (Roswell Park Cancer Institute, Buffalo, NY). All primary cultures were obtained through an IRB approved protocol in abidance with the guidelines at Roswell Park Cancer Institute. Primary cultures of human prostate fibroblasts were passaged in the user’s laboratory not more than three times prior to use for the co-culture experiments. The S3A and T25A cofilin mutant prostate cancer cell lines were generated by site directed mutagenesis in PC-3 cells. Briefly, a point mutation targeting the Ser 3 phosphorylation or the Threonine 25 sites were induced by PCR. To mimic a dephosphorylated (constitutively active) form of cofilin (S3ACFL), a substitution of a Serine on position 3 to Alanine was generated. WT, S3ACFL and T25ACFL mutant forms of cofilin were introduced into PC-3 cells via stable transfection. S3D cofilin mutation, mimicking the constitutive phosphorylated (inactive) form, was introduced in PC-3 cells via transient transfection. Expression vectors for S3D cofilin were generously provided by Dr. Krupenko (MUSC, Charleston, SC) (30). Cells were
transfected with pXIN-HA/cofilin vector DNA using the Effectene Transfection Reagent (QIAGEN 301425, Hilden, Germany). Cofilin expression was silenced by using the siRNA sequence targeting cofilin codons 64-84. An siRNA containing a two single-nucleotide mutation of cofilin (C71G and A73U) was used as control. CAFs are maintained in SCBM CC 3204 (Lonza, Walkersville, MD). Cultured cells were maintained at 30°C in a humidified 5% CO2 incubator. TGF-β ligand and its neutralizing antibody are from R&D Systems (Minneapolis, MN).

**Cell Viability Evaluation.** Cells (10⁴/well) cultured in 96-well plates are exposed to MTT reagent (4hrs) and after dissolving formazan crystals absorbance is read at 490nm (Bio-RAD 680, USA).

**Migration Assays.** Cells seeded in 6-well plates, are wounded at 65-70% density of cell monolayers, and exposed to TGF-β (5ng/ml; 24hrs) in presence or absence of TGF-β neutralizing antibody. The number of migrating cells is counted in three different fields.

**Adhesion Assays.** Cells are incubated in 6-well fibronectin-coated plates, for 30min; non-adherent cells are removed and adherent cells are fixed and evaluated under microscopy.

**Cell Invasion Assays**

(a) **Matrigel Invasion Assay:** The invasion potential is evaluated using a Biocat Matrigel Transwell Chamber (Beckon Dickinson, Franklin Lakes, NJ). Prostate cells are seeded into the upper chamber of a transwell insert pre-coated with fibronectin in serum-free
medium (50,000 cells/well). After 24 hrs non-invading cells are removed from upper chamber and invading cells are stained with Diff-Quick Solution (IMEB Inc., San Marcos, CA).

**(b) Matrigel Cell Tracking:** Human prostate cancer-associated fibroblasts (CAFs) (Supplementary Data, S3) and PC-3 prostate cancer cells are independently grown in medium containing SCBM or RPMI respectively. SCBM medium containing CellTracker™ Green CMFDA dye (5 μM) (Invitrogen, USA) and 1640 RPMI medium containing CellTracker™ Orange CMTML (Invitrogen), are added to CAFs and PC-3 cells, respectively (45 mins). The CellTracker™ Green CMFDA labeled cell suspensions of CAFs are placed into the inner circle of underside membrane of a Biocat Matrigel Transwell Chamber. Inserts are placed in 12-wells in Biocat Matrigel Transwell Chambers in the absence or presence of TGF-β ligand (5 ng/ml). CellTracker™ Orange CMTML labeled WT and S3ACFL PC-3 cells are seeded in the upper chamber and after 24 hrs invading cells are detected using an epifluorescence Nikon Eclipse E600 microscope (Nikon, Melville, NY).

**In-vitro Co-culture Assay**

Human prostate cancer associated fibroblasts (CAFs) (Supplementary Data, Fig. S3) are grown in the inner membrane circle of Biocat Matrigel Transwell Chamber inserts and after 24 hrs, inserts are transferred in Biocat Matrigel Transwell Chambers in absence/presence of TGF-β neutralizing antibody. Prostate cancer epithelial cells are seeded into the upper chamber and after co-culturing for 24 hrs invading cells are stained with Diff-Quick Solution (IMEB Inc, San Marcos, CA).
Western Blot and Immunoprecipitation Analysis

Cell pellets and lung tissue are lysed in RIPA buffer (50mM Tris-HCl, pH7.4, 1%NP40, 0.25% Na-deoxycholate, 150 mM NaCl, 1mM EDTA, 1mM PMSF, (Sigma P8340 protease inhibitor). Cell lysates are subjected to SDS-PAGE and transferred to Immun-Blot PVDF membranes. After exposure to the respective primary antibodies, proteins are detected using the ECL plus Detection System (GE, Amersham, UK). The antibodies used are: anti-cofilin (Sigma Aldrich, St. Louis, MO), phospho–cofilin (Ser 3); anti-LIMK-2 (Cell Signaling, Danvers, MA) and GFP (Santa Cruz Biotechnology, CA). For the immunoprecipitation experiments, PC-3 cells were transfected with Flag-tagged WTCFL, S3ACFL, and T25A CFL, and cells were grown in CSS medium for 24hrs. Cells were subsequently treated with TGFβ1 (for 6hrs) in the absence or presence of MEK inhibitor PD98095. Whole cell lysates were subjected to imunoprecipitation with the anti-Flag antibody, and Western blots with the specific antibodies.

Immunofluorescence Analysis

Cells (7x10^4 cells/well) seeded in 6-well plates are exposed to TGF-β (5ng/ml, 24hrs). Cells are fixed with methanol-free formaldehyde and permeabilized with Triton X-100 (0.1% v/v). Fluorescent staining of filamentous actin is performed using Rhodamine Phalloidin staining of F-actin (Invitrogen). Cofilin expression is detected using the rabbit anti-cofilin antibody following incubation with Alexa Fluor 488 (Invitrogen) (24hrs). Images are processed using a fluorescence Nikon Eclipse E600 microscope (Nikon, Melville, NY).
**Experimental Metastasis Assay**

The metastatic potential of WTCFL and S3ACFL mutant PC-3 cells was examined *in vivo* by the tail vein injection-experimental metastasis assay. Male nude mice (6-wks old) (Harlan Laboratories Inc., Indianapolis, IN) were maintained in sterile cages in pathogen-free environment. Animal experiments were performed under protocols approved by the Institutional Animal Care and Use Committee. GFP labeled WTCFL and S3ACFL PC-3 cells (10^6) were injected into the tail vein of mice (n=6/cell line). At 4-wks post-inoculation, lungs were excised and metastatic lesions to the lungs were examined under the microscope. Lung tissue was homogenized and subjected to Western blot analysis.

**Immunohistochemical Analysis**

(a) **Human Prostate Specimens:** Formalin-fixed paraffin-embedded specimens of human prostate cancer primary and metastatic (n=11), were obtained from the Markey Biospecimen and Tissue Procurement Shared Resource Facility (BSTP SRF). Tissue sections (4µm) were analyzed for cofillin and p-cofilin immunoreactivity using antibodies against cofillin (Sigma) and phosphorylated–cofilin (Ser 3) (Cell Signaling). Palladin expression was detected using the palladin antibody (Proteintech Group Inc., Chicago, IL). E-Cadherin was detected using the E-Cadherin antibody (Cell Signaling). H-scoring was assessed in three fields [cell positivity (Q) and intensity (I), graded as in Figure S5].

(b) **TRAMP Mouse Model.** TRAMP transgenic mice develop prostate adenocarcinoma resembling the clinical progression of human disease to metastasis (33). Tissue sections from TRAMP prostate tumors of increasingly aggressive stage were subjected to immunohistochemical analysis as described above.
Statistical Analysis

Statistical analyses are performed with GraphPad Prism 5 for Windows (GraphPad Software, San Diego, CA). Data are presented as means ±SEM. Numerical values are the mean of three independent experiments. Statistical evaluation of the data is performed using the Student t test and Two-way analysis of variance for multiple comparisons. Significant difference is defined at a P value < 0.05.

Results

Cofilin Activity Directs TGF-β Mediated Actin Severing in Prostate Cancer Cells

Recent work on the actin cytoskeleton dynamics in prostate cancer metastasis led to the characterization of significant protein interactions (in the tumor microenvironment) targeting of which potentially impairs metastatic progression (39-42). The present study identified the functional contribution of CFL to the process of prostate cancer metastasis in the context of processing signals from the microenvironment. Previously we identified CFL as a Smad independent effector of TGF-β mediated apoptosis signaling in prostate cancer cells by virtue of its cytosolic release (38). In order to assess the effect of exogenous TFG-β in CFL phosphorylation status and activity constitutively active (dephosphorylated) forms of CFL were generated in PC-3 prostate cancer cells by mutagenesis via substitution of a Serine on position 3 to Alanine (S3ACFL) and a Threonine to Alanine at position 25 (T25ACFL). Immunoprecipitation analysis of phosphorylated protein associations in response to TGF-β,
revealed that the S3ACFL mutation specifically conferring CFL dephosphorylation, promotes its association with actin (enhancing filament severing), while the T25ACFL mutation, (impairing Threonine phosphorylation) had no effect on the association of p-cofilin with actin (Fig. 1). Moreover, the presence of MEK inhibitor (PD98059) abrogated the TGF-β mediated association between p-Erk and cofilin (Fig. 1). The mutational activation/cofilin dephosphorylation status (S3ACFL or T25ACFL), or silencing CFL expression (shCFL) had no significant consequences on prostate cancer cell viability (Supplementary Fig. S1A). TGF-β treatment significantly increased the WTCFL PC-3 cell invasion (inactive cofilin), while loss of cofilin abolished prostate cancer cell invasion (Supplementary Fig. S1B). PC-3 cells harboring the constitutive dephosphorylated (active) cofilin (S3ACFL) had a modestly enhanced invasive response to TGF-β (Supplementary Fig.S1B). The S3ACFL mutation, as expected, abrogated its phosphorylation by LIMK-2, without affecting total cofilin expression (Fig. 2A); there was a compensatory upregulation of LIMK-2 levels in the S3ACFL PC-3 cells compared to WTCFL (Fig. 2A). Figure 2B reveals the endogenous upregulation of downstream signaling effectors RhoA and ROCK1 induced by the introduction of cofilin mutations; both S3DCFL and S3ACFL cells exhibited a significant increase in protein expression for RhoA and ROCK1, compared to WTCFL cells. In response to TGF-β, there was a transient induction in phosphorylated CFL within 3-6hrs, that was preceded by a significant increase in ROCK 1 and Rho A levels, in the WTCFL but not in the S3ACFL cells (Fig. 2, panels C and D). This temporal phosphorylation of CFL in response to TGF-β was also detected in another human prostate cancer cell line that has restored sensitivity to the cytokine, LNCaP TβRII (Supplementary Fig.S2).
Active Cofilin Dictates Prostate Cancer Cell Migration and Invasion Responses to TGF-β (via Reactive Stroma)

The effect of TGF-β on prostate cancer cell migration was analyzed in two different human prostate cancer cell lines with normal CFL function, LNCaP TβRII and WTCFL PC-3 cells; Treatment with TGF-β (24hrs) led to a significant decrease in prostate cancer cell migration for both cell lines (Fig. 3, panels A and B). Functional blocking of TGF-β by the neutralizing antibody against the cytokine, restored migration capacity to control levels in both cell lines LNCaP TβRII and WTCFL PC-3 (Fig. 3). To determine the effect of a mutation in CFL phosphorylation site on prostate cancer cell migration, we comparatively assessed the migration ability of S3ACFL mutants mimicking the constitutively active form of cofilin and as a functional control, S3DCFL mimicks the constitutively inactive form. The S3A cofilin mutation resulted in a significant increase in PC-3 cell migration (Fig. 3B), while the induced-loss of TGF-β (by neutralizing antibody), further increased S3ACFL cell migration (Fig. 3B). In contrast, a significant decrease in both cell migration (Supplementary Fig.S3A) and cell adhesion to ECM (Supplementary Fig.S3B) was observed for the inactive S3DCFL cells compared to the S3ACFL cells. The impact of S3ACFL mutation on prostate cancer cell invasion was interrogated in the context of tumor microenvironment. The quantitative data from the invasion assay indicate no significant difference in the invasion potential of S3ACFL cells compared to WTCFL PC-3 cells (Fig. 4A). The increase in invading cell number in response to exogenous TGF-β was abrogated by the presence of the neutralizing antibody against TGF-β, in both WTCFL and S3ACFL cells (p<0.05).

The reactive stroma contributes to prostate cancer progression through the cancer-associated fibroblasts that facilitate metastasis (39, 40). To assess whether the effect of CFL
on prostate tumor cell invasion is TGF-β-dependent as mediated from surrounding cancer associated fibroblasts (Supplementary Fig. S4), prostate cancer cell invasion was evaluated in \textit{in vitro} co-cultures. Fluorescent labeled PC-3 prostate cancer epithelial cells (red) were co-cultured with labeled human prostate cancer associated fibroblasts (green) in the upper chamber of a matrigel pre-coated transwell insert for 24hrs (Fig. 4B). Only prostate tumor epithelial cells invaded the matrigel. There was no significant difference in cell invasion between WTCFL and S3ACFL cell lines (but there was a decrease in the S3D mutant cells). In the presence of human prostate cancer associated fibroblasts (CAFs) however, there was a significant increase in the number of tumor epithelial cells invading, for both WTCFL PC-3 and LNCaPTβRII cells (Fig. 4, panels C and D, respectively). The S3D CFL mutation (phosphorylation) had no effect on prostate cancer cell invasion regardless of TGF-β status (Fig. 4C). Simultaneous exposure to the TGF-β neutralizing antibody yielded an additional significant increase in the S3ACFL cell invasion potential (p< 0.004). In contrast in two different prostate cancer cell lines with normal cofilin function WTCFL PC-3 cells and LNCaPTβRII cells, we observed the expected reduction in invasion. These data demonstrate that only active cofilin was able to functionally direct TGF-β signaling (secreted by the CAFs in the microenvironment) in promoting invasive behavior.

\textbf{Cofilin Mediates Prostate Cancer Cell Adhesion via Cytoskeletal Remodeling}

Cell adhesion is directly dependent on cofilin activity and cytoskeletal actin since depolimeryzation and polymerization of new actin filaments is required for filopodia formation (41). We subsequently investigated the effect of S3A mutation on prostate cancer cell adhesion to fibronectin (ECM) and filopodia formation. S3ACFL cells exhibited a
significantly increased cell adhesion to fibronectin compared to control WTCFL cells (Fig. 5A). This correlated with cytoskeletal remodeling as indicated by fluorescence staining of F-actin and formation of filopodia (Fig. 5B). Confocal microscopy revealed an increased number of filopodia protrusions in S3ACFL PC-3 (arrows) compared to WTCFL PC-3 cells (Fig. 5B). High coflin expression was detected at cell membrane regions populated by filopodia. Treatment with TGF-β led to a significant decrease in S3ACFL cell adhesion (Fig. 5A), and a reduction in filopodia protrusions (Fig. 5B). To determine whether this CFL co-localization with filopodia is dependent on endogenously derived TGF-β from the surrounding prostate cancer associated fibroblasts (reactive stroma), we used confocal microscopy to profile the CFL/rhodamine phalloidin co-localization, in S3ACFL prostate epithelial cancer cells co-cultured with human CAFs. As shown on Figure 5C, coflin (green) colocalizes with filopodia protrusions (arrows) and loss of TGF-β resulted in increased actin/cofilin colocalization (yellow) with filopodia protrusions in S3ACFL cells in this reactive stroma-tumor microenvironment.

**Active Cofilin Enhances Prostate Cancer Metastasis In Vivo**

In the experimental metastasis assay, prostate cancer cells harboring the S3ACFL mutation exhibited an increased metastatic ability in vivo, compared to WTCFL PC-3 prostate cancer cells, as determined by the higher number of lung metastases (Fig. 6A). Sustained exposure of prostate cancer cells with active coflin, to TGF-β abundantly secreted in vivo, may promote their invasive properties towards metastasis (Fig. 6B)
**Cofilin Overexpression Correlates with Prostate Cancer Progression to Metastasis**

TRAMP transgenic mice develop prostate adenocarcinoma with increasing age, resembling progression of human prostate cancer to metastasis. Elevated CFL expression during prostate cancer progression in the TRAMP model, was associated with prostate tumor aggressiveness with increasing age (16-28 wks) (Fig. 7A). Quantitative analysis indicated a significant increase in CFL levels in metastatic tumors (28-wks) compared to early stage tumors and normal prostate (16-wks WT) (Fig. 7, panels A and B). Immunohistochemical profiling of CFL in human prostate tissue specimens from a patient cohort with localized and metastatic disease to the lymph nodes and quantitative assessment of the staining (Supplementary Fig.S5), revealed a striking increase in CFL expression in metastasis compared to primary cancer in the same patient (Fig. 7, panels C and D). Characteristic images of CFL immunoreactivity in serial sections of primary prostate tumors and metastasis are shown on Figure 7, panels C and D. CFL levels were significantly increased in metastasis compared to primary prostate cancer (p=0.006), while there were no significant differences in the expression of p-CFL or palladin proteins between primary and metastatic prostate cancer (Fig. 7E).
Discussion

This study characterizes the ability of active CFL to direct prostate cancer cell migratory and invasive responses to TGF-β. The results revealed that constitutively active cofilin (S3ACFL) confers significant differences in actin remodeling proteins, migration, invasion and metastatic potential in human prostate cancer cells in vitro and in vivo. The evidence links CFL activation to acquisition of an enhanced aggressive phenotype of prostate cancer cells in a TGF-β dependent context. In response to TGF-β active CFL binds to F-actin at the leading edge conferring increased tumor cell migration. Our findings that active cofilin (S3A mutation) does not exert significant consequences on prostate cancer cell invasion, but rather directs the invasive responses to TGF-β, contradictory as they might seem, are not unexpected. In breast cancer cells, CFL activation by epidermal growth factor (EGF), leads to increased number of actin filament barbed ends via the polymerization of G actin monomers that generates new actin filaments and dynamic filament branching at the tip of the leading edge (43). Indeed, cell migration relies on the coordinated remodeling of the actin cytoskeleton and leading edge protrusions of moving cells are formed by lamellipodia and filopodia directing cell motility (24, 41). This study revealed a marked increase in filopodia formation in S3ACFL PC-3 cells and enhanced actin binding to the active cofilin, implicating cofilin dephosphorylation dictating prostate cancer cell migration without the regulatory effect of TGF-β, as actin severing proceeds uncontrolled. Considering that filopodia enable not only cell motility, but also facilitate attachment to the ECM and promote colonization and formation of secondary tumors at distant sites (41), our findings provide a significant insight into the ability of active CFL to promote prostate cell attachment to fibronectin, by
remodeling critical cell-ECM adhesion sites and metastatic dissemination in vivo. The protein-protein interactions coordinating these events are being pursued.

Our data frame a microenvironment landscape in which CFL activation (due to mutations on phosphorylation site), promotes prostate cancer cell migration and metastatic spread by increasing severing activity and actin interactions. Cancer associated fibroblasts substantially enhance the invasive properties of prostate cancer cells with constitutively active coflin, possibly via a sustained release of TGF-β. This evidence provides a proof-of-principle on a direct pro-invasive crosstalk between surrounding cancer associated fibroblasts and prostate cancer cells with TGF-β functioning as a tumor suppressor by activating the RhoA/ROCK1 signaling, leading to phosphorylation and activation of LIMK-2. This impairs coflin severing activity, cytoskeletal reorganization and formation of filopodia, decreasing tumor cell migration (shown schematically on Fig. 6B). During prostate cancer progression active coflin directs an action switching for TGF-β to elicit metastatic responses, by enabling actin cytoskeleton remodeling and invasive tumor cell behavior. Taken together these results provide a first insight into the role of TGF-β to impair prostate cancer growth in the early stages by putting the “breaks” on coflin activity (via phosphorylation) and consequently compromising actin severing action. During the late stages of tumor progression, a mutation conferring constitutive activation of coflin, enables the escape to TGF-β-regulated phosphorylation by LIMK-2. In sharp contrast to an expected “action independence” from this cytokine, sustained exposure of prostate cancer cells, now harboring active coflin (S3CFL mutation), to TGF-β secreted by the stroma microenvironment, promotes their migratory and invasive properties towards metastasis (Fig. 6B). Collectively this evidence implies that mutational activation of coflin occurring during prostate cancer progression is
sufficient for navigating a functional switch for TGF-β from growth suppressor to a metastasis promoter. Interestingly enough, recent elegant studies implicate an additional “underestimated” contributor from the prostate microenvironment, the autonomic nerve development promoting cancer progression to metastasis (44).

The immunohistochemical profiling identified a direct association between cofilin overexpression and cancer progression to metastasis in the TRAMP mouse model of prostate tumorigenesis. More importantly of direct clinically relevance is the data demonstrating a significant increase in cofilin expression in human prostate cancer metastasis (to lymph nodes), compared to primary tumors (same patient cohort). Changes in cofilin expression have been reported in other human malignancies including colon and ovarian cancer (45-48). Loss of the epithelial marker E-cadherin is associated with a more invasive phenotype in prostate cancer cells and high grade and metastatic prostate cancer, as originally established (49). The strong correlation between cofilin overexpression with the in vivo metastatic and invasive properties of prostate cancer cells provides a new platform of interrogation of the cytoskeletal dynamics in cancer metastasis and the potential clinical value of cofilin in tumor progression. Indirect support for our findings is gained from recent evidence correlating cofilin with ovarian cancer progression, and a longer progression free survival in low-expression cofilin patient cohort (47). Moreover recent evidence supports a close functional impact of cytoskeletal dynamics on cancer metastasis under the control metabolic stress (50). Ongoing investigations are focused on two translational pursuits: (a) the correlation of cofilin and p-cofilin expression with disease-free survival and biochemical recurrence in a large cohort of prostate cancer patients with advanced disease; and (b) the incidence of cofilin mutations (at phosphorylation sites) in human prostate tumors.
Grant Support

This work was supported by an NIH grant R01 DK 083761 and DOD W81XWH-08-1-0431 (NK), an NCI K08 grant CA155764 (CH), 2P20 RR020171 COBRE (National Institute of General Medical Sciences), Peter and Carmen Lucia Buck Training Program in Translational Clinical Oncology (CH), the University of Kentucky College of Medicine Physician Scientist Program (SL, CH) and a Lyman T. Johnson Minority Fellowship (JC).

Acknowledgments

This research was supported by the Biospecimen and Tissue Procurement Shared Resource Facility of the University of Kentucky Markey Cancer Center (P30CA177558). Special thanks to Dr. Sergey Krupenko (Department of Biochemistry, Medical University of South Carolina) for generously providing the S3DCFL plasmid and useful discussions; Dana Napier (Department of Pathology, University of Kentucky College of Medicine) for her excellent histologic expertise; Patrick Hensley, University of Kentucky College of Medicine, for his expertise and help in the preparation/formatting of the figures and Lorie Howard for her assistance in the electronic submission of the manuscript.

Authors’ Contributions

Conception and Design: N. Kyprianou, B. Zhu, J. Collazo

Development and Methodology: N. Kyprianou, J. Collazo, B. Zhu, H. Pu

Acquisition of Data: J. Collazo, B. Zhu, C. Horbinski, S. Koochekpour, S. Martin, S. Larkin

Writing, Review of Manuscript: N. Kyprianou, J. Collazo, S. Koochekpour

Administrative Support: N. Kyprianou, C. Horbinski

Study Supervision: N. Kyprianou
References


30. Oleinik, NV, Krupenko NI, Krupenko SA. ALDH1L1 inhibits cell motility via dephosphorylation of cofilin by PP1 and PP2A. Oncogene 2010;25:6233-44.


Figure Legends

Figure 1. S3A Cofilin Dephosphorylation Specifically Directs Actin Severing Response to TGF-β. PC-3 cells were transfected with Flag tagged WTCFL, S3ACFL, or T25ACFL and were subsequently treated with TGFβ1 (5ng/ml) for 6hrs in the presence or absence of PD98095 inhibitor. Cell lysates (50µg of protein) were subjected to immunoprecipitation with anti-Flag antibody, and subsequent Western blotting with the indicated antibodies. Phosphorylated proteins p-Erk, protein 14-3-3, actin and p-cofilin are induced in response to TGF-β in WTFL prostate cancer cells. S3ACFL mutation conferring constitutive cofilin dephosphorylation specifically diminishes p-cofilin and enables active cofilin binding to actin without TGF-β regulation. In contrast, the T25A CFL mutation impairs threonine phosphorylation that does not impact actin binding, and thus both p-cofilin (Ser 3) and actin are detected.

Figure 2. Effect of S3A Mutation on Cofilin Phosphorylation Events in PC-3 Cells. Effect of TGF-β on cofilin, p-cofilin and LIMK-2 protein expression in prostate cancer cells. Panel A, Upregulation of LIMK-2 protein in mutant S3ACFL PC-3 cells. Treatment with TGF-β (5ng/ml) increased LIMK-2 and p-cofilin expression in the WT and decreased LIMK-2 expression in the S3ACFL cells. Panel B, Western blotting indicating elevated RhoA and ROCK1 protein in S3ACFL PC-3. Panels C and D, Treatment with TGF-β increased RhoA and ROCK1 levels in WTCFL cells and decreased expression of both proteins in S3ACFL cells. GAPDH was used as loading control.
**Figure 3. Cofilin Drives TGF-β-Mediated Prostate Cancer Migration.** Panel A, Human prostate cancer cells LNCaP TβRII (normal coflin) exhibited a significant reduction in cell migration in response to TGF-β. In the presence of a neutralizing antibody against TGF-β, cell migration was restored to untreated control levels. Values shown are the number of migrating cells from two independent experiments performed in triplicate. Panel B, S3ACFL mutation enhances prostate cancer cell migration bypassing TGF-β. Upper panel, representative images of increased cell migration ability for S3ACFL PC-3 cells compared to WTCFL cells (24hrs). Lower panel, TGF-β treatment significantly decreased WTCFL cell migration (p<0.0008), but it had no significant effect in S3ACFL cells. Loss of TGF-β (by neutralizing antibody) restored the WTCFL PC-3 cell migration capacity, while it increased S3CFL mutant cell migration (p=0.005).

**Figure 4. Cofilin Navigates Invasive Response to TGF-β (from Stroma Microenvironment).** Panel A, The invasive response of prostate cancer cells to TGF-β assessed in the matrigel assay. S3ACFL had no significant effect on PC-3 cell invasion (black barographs). In response to exogenous TGF-β, there was an increase in WTCFL PC-3 cell invasion potential, but not in S3ACFL cells (p=0.03). In the presence of TGF-β neutralizing antibody, there was a significant decrease in the invasion potential for both WTCFL and S3ACFL cells (p=0.04 and p=0.004, respectively). Panel B, Matrigel invasion of WTCFL PC-3/CAFs, (right) and S3ACFL PC-3/CAFs co-cultures (left) after 24hrs. CAFs significantly increased prostate cancer cell invasion for both WTCFL and S3ACFL cells (p=0.004 and p=0.007. Continuous secretion of TGF-β by the reactive microenvironment (in presence of TGF-β neutralizing antibody), induced a further increase in the number of
invading S3ACFL cells (p=0.008), while it decreased WTCFL cell invasion. Values are the average from two independent experiments in triplicate. Panel C, Co-cultures of WTCFL, S3ACFL and S3DCFL with CAFs in the presence or absence of a neutralizing TGF-β antibody. Quantitative assessment of invading cells indicates that only active cofilin (S3ACFL) directs a further increase in TGF-β mediated cell invasion (derived from CAFs). Panel D, A significantly higher increase in cell invasion is stimulated by CAFs in co-cultures with the LNCaP TβRII cells (highly responsive to TGF-β). This was abrogated by the presence of the neutralizing antibody against TGF-β. * significant difference at p<0.007.

**Figure 5. Active Cofilin Mediates Prostate Cancer Cell Adhesion via Cytoskeletal Remodeling, an Effect Impaired by TGF-β.** Panel A, effect of S3ACFL on prostate cancer cell adhesion. S3A mutation conferred a significant increase in cell adhesion to fibronectin compared to WTCFL cells (p=0.0003). TGF-β significantly decreased in S3CFL cell adhesion (p=0.0004), but not in WTCFL cells. Values shown are the mean (+/-SEM) of three independent experiments performed in triplicates. Statistical significance set at a p value of p<0.005. Panel B, Active cofilin enhances filopodia formation; representative images of confocal microscopy (40x) show increased number of filopodia protrusions in S3ACFL PC-3 (arrows) compared to WTCFL cells. Treatment with TGF-β (5ng/ml; 24hrs) decreased filopodia protrusions in S3ACFL cells. Filopodia were quantitated in five random fields were examined for each cell line and values shown are mean +/- SEM from three independent experiments (left). Statistical significance is defined at P<0.01. Panel C, S3ACFL active binding to F-actin at the leading edge of the cells is mediated by TGF-β. Cofilin co-localization with filopodia is dependent on TGF-β derived from surrounding stroma (CAFs).
Images of coflin/rhodamine phalloidin co-colocalization, in S3ACFL prostate epithelial cancer cells co-cultured with CAFs. Cofilin (green) colocalizes with filopodia protrusions (arrows). Loss of TGF-β (in presence of neutralizing antibody) increases actin/cofilin colocalization (yellow) and filopodia protrusions in S3ACFL cells.

**Figure 6. Cofilin Constitutive Activation Promotes Prostate Cancer Metastasis.** Panel A, Male nude mice (n=12) were inoculated with GFP-labeled PC-3 cells (parental, WTCFL and S3ACFL) via tail vein injections. Metastatic lesions to the lungs were assessed at 4-wks post-inoculation. S3ACFL cells generated a significantly higher number of metastases compared to control PC-3 cells (p=0.04). Values show the number of metastatic lesions to the lung/mouse for each cell line. Western blots of mouse lung tissue homogenates and cell lysates indicate the GFP presence in all samples (left). Panel B, Schematic diagram illustrating the regulatory impact of coflin on TGF-β functional switch towards prostate cancer cell migration, invasion and metastasis. Under constitutive activated coflin (S3ACFL), TGF-β produced by the reactive stroma/microenvironment (CAFs), unable to dephosphorylate coflin, increases tumor cell aggressiveness and metastatic potential.

**Figure 7. Cofilin Overexpression Correlates with Prostate Cancer Progression to Metastasis.** Panels A and B, Cofilin profiling in TRAMP mouse model. TRAMP transgenic mice develop prostate adenocarcinoma with increasing age, resembling progression of human prostate cancer to metastasis. Prostate sections of increasing grade and metastatic tumors (16-28wks) were profiled by immunostaining for coflin expression; WT mouse prostate tissue (16wks) was used as control. (magnification X40). Quantitative evaluation of
CFL immunoreactivity, as determined by the H-scoring, shows a significant increase in metastatic tumors from 28-wks old TRAMP mice ($p=0.001$) compared to early stage tumors. Panels C, D and E: Cofilin expression profile in human prostate cancer. Panel C, H&E staining and CFL immunostaining in serial sections of prostate tumors; characteristic image of a metastatic lesion to lymph nodes exhibiting intense cofilin immunoreactivity, compared to the primary tumor from the same patient (absence of CFL expression). Magnification 100X, Panel D indicates representative images of immunostaining for cofilin, p-cofilin, E-cadherin and palladin on primary and metastatic prostate cancer. Panel E, quantitative analysis of protein immunoreactivity (from Panel D). There was a significant increase in cofilin levels in metastatic specimens compared to primary tumors ($p=0.005$).
### Figure 1

<table>
<thead>
<tr>
<th></th>
<th>TGF-β1</th>
<th>PD98059</th>
<th>WCFL-FLAG</th>
<th>S3ACFL-FLAG</th>
<th>T25ACFL-FLAG</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>p-Erk</strong></td>
<td><img src="image1" alt="Image" /></td>
<td><img src="image2" alt="Image" /></td>
<td><img src="image3" alt="Image" /></td>
<td><img src="image4" alt="Image" /></td>
<td><img src="image5" alt="Image" /></td>
</tr>
<tr>
<td><strong>14-3-3</strong></td>
<td><img src="image6" alt="Image" /></td>
<td><img src="image7" alt="Image" /></td>
<td><img src="image8" alt="Image" /></td>
<td><img src="image9" alt="Image" /></td>
<td><img src="image10" alt="Image" /></td>
</tr>
<tr>
<td><strong>Threonine actin</strong></td>
<td><img src="image11" alt="Image" /></td>
<td><img src="image12" alt="Image" /></td>
<td><img src="image13" alt="Image" /></td>
<td><img src="image14" alt="Image" /></td>
<td><img src="image15" alt="Image" /></td>
</tr>
<tr>
<td><strong>p-CFL (s3)</strong></td>
<td><img src="image16" alt="Image" /></td>
<td><img src="image17" alt="Image" /></td>
<td><img src="image18" alt="Image" /></td>
<td><img src="image19" alt="Image" /></td>
<td><img src="image20" alt="Image" /></td>
</tr>
<tr>
<td><strong>Flag</strong></td>
<td><img src="image21" alt="Image" /></td>
<td><img src="image22" alt="Image" /></td>
<td><img src="image23" alt="Image" /></td>
<td><img src="image24" alt="Image" /></td>
<td><img src="image25" alt="Image" /></td>
</tr>
</tbody>
</table>
Figure 2

A

<table>
<thead>
<tr>
<th></th>
<th>WTCFL PC-3</th>
<th>S3ACFL PC-3</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGF-β</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>24</td>
</tr>
<tr>
<td>LIMK-2</td>
<td>70kDa</td>
<td>70kDa</td>
</tr>
<tr>
<td>p-Cofilin</td>
<td>19kDa</td>
<td>19kDa</td>
</tr>
<tr>
<td>Cofilin</td>
<td>19kDa</td>
<td>19kDa</td>
</tr>
<tr>
<td>Actin</td>
<td>42kDa</td>
<td>42kDa</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>WTCFL S3DCFL S3ACFL</th>
</tr>
</thead>
<tbody>
<tr>
<td>RhoA</td>
<td>22kDa</td>
</tr>
<tr>
<td>ROCK1</td>
<td>158kDa</td>
</tr>
<tr>
<td>GAPDH</td>
<td>37kDa</td>
</tr>
</tbody>
</table>

C

<table>
<thead>
<tr>
<th></th>
<th>WTCFL PC-3</th>
<th>S3ACFL PC-3</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGF-β</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>24</td>
</tr>
<tr>
<td>RhoA</td>
<td>22kDa</td>
<td>22kDa</td>
</tr>
<tr>
<td>GAPDH</td>
<td>37kDa</td>
<td>37kDa</td>
</tr>
</tbody>
</table>

D

<table>
<thead>
<tr>
<th></th>
<th>WTCFL PC-3</th>
<th>S3ACFL PC-3</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGF-β</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>24</td>
</tr>
<tr>
<td>ROCK1</td>
<td>158kDa</td>
<td>158kDa</td>
</tr>
<tr>
<td>GAPDH</td>
<td>37kDa</td>
<td>37kDa</td>
</tr>
</tbody>
</table>
Figure 3

A

P = 0.0013  P = 0.0082

Average # of Migrating Cells

Control  TGF-β  TGF-β ab +

B

WTcFL PC-3

S.3ACFL PC-3

- TGF-β  + TGF-β  + TGF-β / + TGF-β Ab

Average # of Migrating Cells

Control  TGF-β  TGF-β ab +

Downloaded from cancerres.aacrjournals.org on October 30, 2017. © 2014 American Association for Cancer Research.
Figure 4

A

B

C

D

Downloaded from cancerres.aacrjournals.org on October 30, 2017. © 2014 American Association for Cancer Research.
Figure 6

A

Lung Tissue Homogenates

PC-3  WTCLF  S3ACFL
GFP  27kDa
Cofilin  19 kDa
GAPDH  37kDa

Cell Lysates

PC-3  WTCLF  S3ACFL
GFP  27kDa
Cofilin  19 kDa
GAPDH  37kDa

Number of Lung Metastases / Mouse

WTCLF PC-3  S3ACFL PC-3

P=0.04

B

Wild Type Cofilin

TGF-β / CAFs

RhoA
ROCK1
LIMK

Cofilin Phosphorylation

DECREASED Actin Severing

Migration  Invasion

Constitutively Active Cofilin (S3ACFL)

TGF-β / CAFs

RhoA
ROCK1
LIMK

Cofilin Phosphorylation

INCREASED Actin Severing

Migration, Invasion, Metastasis

Downloaded from cancerres.aacrjournals.org on October 30, 2017. © 2014 American Association for Cancer Research.
Figure 7

A

16w WT 16w 20w 24w 28w

TRAMP+

B

C

H&E  Cofflin

Primary

Metastasis

D

Primary  Metastasis

H&E  Cofflin

P-Cofflin

Paladin

E-Cathelin

E

Downloaded from cancerres.aacrjournals.org on October 30, 2017.
# Cofilin Drives Cell Invasive and Metastatic Responses to TGF-β in Prostate Cancer

Joanne Collazo, Beibei Zhu, Spencer Larkin, et al.

_Cancer Res_ Published OnlineFirst February 7, 2014.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-13-3058</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://cancerres.aacrjournals.org/content/suppl/2014/02/11/0008-5472.CAN-13-3058.DC1">http://cancerres.aacrjournals.org/content/suppl/2014/02/11/0008-5472.CAN-13-3058.DC1</a></td>
</tr>
<tr>
<td>Author Manuscript</td>
<td>Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>